Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zimmer Offers Update On Anticipated Device Tax Impact For 2013

This article was originally published in The Gray Sheet

Executive Summary

The orthopedic device maker now forecasts the financial impact of the impending device excise tax in 2013 will be less for Zimmer than previously anticipated, since about half of it can be deferred by six months under the firm’s updated accounting plan.

You may also be interested in...

Zimmer Emphasizes Persona Knee System Rollout For 2013

The continued rollout of the firm’s new Persona knee system will be critical to its 2013 earnings, Zimmer executives tell investors.

News In Brief

More DME competitive bidding planned. AdvaMed outlines strategic plan. Roche ends Illumina bid, for now.

Device Tax Will Present "Manageable" Challenges, Analysts Say

The final health care reform device industry tax provision, while presenting a challenge, will be manageable by the sector at large, according to industry analysts


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts